YDES NASDAQ
YD Bio Limited Ordinary Shares
1W: -9.5%
1M: -13.9%
3M: -42.9%
YTD: -61.8%
$4.75
+0.17 (+3.71%)
Weekly Expected Move ±6.3%
$5
$5
$5
$6
$6
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Smart Money Score
Watch
25
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$336.4M
52W Range4.37-25
Volume4,454
Avg Volume17,774
Beta-0.06
Dividend—
Analyst Ratings
No analyst coverage
Company Info
CEOEthan Shen
Employees4
SectorHealthcare
IndustryBiotechnology
IPO Date2025-08-29
Websiteydesgroup.com
No. 3, Xingnan St.
Taipei 115001
TW
Taipei 115001
TW
+82 2 546 1611
About YD Bio Limited Ordinary Shares
Breeze Holdings Acquisition Corp. operates as a clinical-stage biopharmaceutical company focuses on cancer prevention medical diagnostics and the development of exosome-based therapeutics with the potential to transform the treatment of a diseases with unmet medical need. The company is based in Taipei, Taiwan.
Latest News
YD Bio Limited GAAP EPS of -$0.12, revenue of $0.6M
YD Bio Limited Reports Full Year 2025 Financial Results
YD Bio Limited Reports Full Year 2025 Financial Results
Autoliv Posts Upbeat Q1 Results, Joins United Airlines, Royal Caribbean Cruises And Other Big Stocks Moving Higher On Friday
12 Health Care Stocks Moving In Tuesday's Intraday Session
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Lu Shao-Ta | A-Award | 2,081 | — | 2026-03-31 |
| Lu Shao-Ta | M-Exempt | 2,081 | — | 2026-03-31 |
| Chang Kochi | A-Award | 2,081 | — | 2026-03-31 |
| Chang Kochi | M-Exempt | 2,081 | — | 2026-03-31 |
| Lu Shao-Ta | 0 | — | 2026-03-18 |